Gargiulo P, Schiaffini R, Bosco D, Ciampalini P, Pantaleo A, Romani B, Arcieri P, Andreani D
Endocrinology 1 - Thrombosis Centre, Roma, Italy.
Diabet Med. 1997 Feb;14(2):132-7. doi: 10.1002/(SICI)1096-9136(199702)14:2<132::AID-DIA312>3.0.CO;2-6.
Type 1 (insulin-dependent) diabetes mellitus is associated with long-term vascular complications. In addition to metabolic factors, immunological and haemostatic mechanisms may be involved. Lupus anticoagulant (LA), an immunoglobulin which interferes with endothelial cell function, is frequently associated with a high risk of thromboembolic events. LA has been described in several diseases but never in diabetes mellitus. The aim of this study was to evaluate if endothelial dysfunction and unmodulated haemostasis are amplified by the presence of LA in Type 1 diabetic patients. Plasma samples collected from clinically and biochemically well-characterized Type 1 diabetic patients were examined for LA, fibrinogen, prothrombin (PT), PTT, prothrombin degradation products (F1 + 2) and activated protein C (APC). The results revealed significantly decreased APC and increased F1 + 2 plasma concentrations in LA-positive but not in LA-negative patients; 60% of LA-positive and only 18% of LA-negative patients had microangiopathy (not significant). No thrombotic episodes in large vessels were found in LA-positive patients. These findings suggest that LA could be considered an additional factor in the onset and/or progression of diabetic complications, acting as a link between the immunological and haemostatic systems in the pathogenesis of diabetic microangiopathy.
1型(胰岛素依赖型)糖尿病与长期血管并发症相关。除代谢因素外,免疫和止血机制可能也参与其中。狼疮抗凝物(LA)是一种干扰内皮细胞功能的免疫球蛋白,常与血栓栓塞事件的高风险相关。LA已在多种疾病中被描述,但从未在糖尿病中被描述过。本研究的目的是评估1型糖尿病患者中LA的存在是否会加剧内皮功能障碍和未调节的止血。从临床和生化特征明确的1型糖尿病患者中采集血浆样本,检测LA、纤维蛋白原、凝血酶原(PT)、活化部分凝血活酶时间(PTT)、凝血酶原降解产物(F1 + 2)和活化蛋白C(APC)。结果显示,LA阳性患者的APC血浆浓度显著降低,F1 + 2血浆浓度升高,而LA阴性患者则无此现象;60%的LA阳性患者和仅18%的LA阴性患者患有微血管病变(无显著性差异)。LA阳性患者未发现大血管血栓形成事件。这些发现表明,LA可被视为糖尿病并发症发生和/或进展的一个额外因素,在糖尿病微血管病变的发病机制中作为免疫和止血系统之间的联系。